Nuclear Receptors and Signaling
Open access
Peer reviewed
Scollr summary
What this paper is about
In vivo proof-of-concept for SNCA-targeted transcriptional repression therapy in a PD-mouse model is provided and its further preclinical development toward investigational new drug enablement is supported.
Full abstract
Read the full abstract
Alpha-synuclein (SNCA) overexpression is implicated in Parkinson's disease (PD) pathogenesis, making SNCA downregulation a promising therapeutic strategy. We developed a SNCA-targeted transcriptional repression therapy using an all-in-one lentiviral vector (LV) carrying deactivated CRISPR/(d)Cas9, gRNA targeted at SNCA-intron1, and either the catalytic domain of DNA-methyltransferase3A (DNMT3A), or an engineered repressor molecule, a fusion of MeCP2's transcription repression domain (TRD) and KRAB. Therapeutic efficacy was evaluated following co-administration of the therapeutic and model vectors in a new PD mouse model, generated with an adeno-associated viral vector carrying an engineered minigene comprised of the human (h)A53T-SNCA expressed via the human native regulatory region. Both therapeutic vectors reduced expression of α-synuclein in the substantia nigra (SN), with LV/dSaCas9- KRAB-MeCP2(TRD) demonstrating greater repression. LV/dSaCas9- KRAB-MeCP2(TRD) also significantly reduced pathological α-synuclein aggregation and phosphorylation (Ser 129), and preserved tyrosine hydroxylase expression in the SN and the striatum. Behavioral analysis following LV/dSaCas9-KRAB-MeCP2(TRD) injection, showed significant improvement in motor deficits characteristic of our PD-mouse model. Preliminary safety assessments found normal blood counts, serum chemistry, and weights. Collectively, these findings provide in vivo proof-of-concept for SNCA-targeted transcriptional repression therapy in a PD-mouse model and support its further preclinical development toward investigational new drug enablement.
Direct answer
What can I do from this paper page?
Use this page to scan "SNCA-targeted transcriptional repression therapy alleviates pathological and behavioral perturbations in a Parkinson's disease mouse model" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Nuclear Receptors and Signaling research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{ODonovan2026SNCA,
title = {SNCA-targeted transcriptional repression therapy alleviates pathological and behavioral perturbations in a Parkinson's disease mouse model},
author = {Bernadette O’Donovan and Joseph Rittiner and Suraj Upadhya and Dellila Hodgson and Boris Kantor and Ornit Chiba‐Falek},
journal = {Neurotherapeutics},
year = {2026},
doi = {10.1016/j.neurot.2026.e01049},
url = {https://doi.org/10.1016/j.neurot.2026.e01049}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Nuclear Receptors and Signaling research papers?
Follow Nuclear Receptors and Signaling research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for SNCA-targeted transcriptional repression therapy alleviates pathological and behavioral perturbations in a Parkinson's disease mouse model. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app